NCT06259981View on ClinicalTrials.gov

A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

October 23, 2024

Study Completion Date

October 23, 2024

Conditions

Obesity

Interventions

DRUG

GLY-200

2.0 g GLY-200 (4 x 0.5 g capsules) orally twice daily

DRUG

Placebo

4 placebo capsules orally twice daily

Trial Locations (5)

33761

Tampa Bay Medical Research, Inc., Clearwater

34761

Sensible Healthcare, LLC, Ocoee

59701

Mercury Street Medical, Butte

70072

Tandem Clinical Research, Marrero

78229

Clinical Trials of Texas, Inc., San Antonio

All Listed Sponsors

lead

Glyscend, Inc.

INDUSTRY

NCT06259981 - A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity | Biotech Hunter | Biotech Hunter